Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Effective Targeting of KRASG12C Elusiveness.

Cancer cell - 14 Dec 2020

Elez Elena, Tabernero Josep

Abstract excerpt

Developing therapies to directly target KRAS is challenging. In The New England Journal of Medicine, Hong et al. report a promising KRAS-targeting therapy phase I trial. However, a deeper understanding of the underlying biology of each histological context might well be required to optimize the potential benefit of this class of agents.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Mutation
Share to Proto-Oncogene Proteins p21(ras)

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33321088
DOI: 10.1016/j.ccell.2020.11.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Effective Targeting of KRASG12C Elusiveness.PMID 33321088Read ↗

Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy.Semantic proximity Read ↗

Unlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies.Semantic proximity Read ↗

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.Semantic proximity Read ↗

Next batter up! Targeting cancers with KRAS-G12D mutations.Semantic proximity Read ↗

Emerging landscape of KRAS inhibitors in cancer treatment.Semantic proximity Read ↗

Targeting mutant KRAS.Semantic proximity Read ↗

"Undruggable KRAS": druggable after all.Semantic proximity Read ↗

KRAS mutation: from undruggable to druggable in cancerSemantic proximity Read ↗

The Next Generation of KRAS Targeting: Reasons for Excitement and Concern.Semantic proximity Read ↗

Resistance looms for KRAS G12C inhibitors and rational tackling strategies.Semantic proximity Read ↗

Targeting KRAS: Good, But Is It Good Enough?Semantic proximity Read ↗

KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.